Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Multiple MyelomaNon-Hodgkin's Lymphoma
Interventions
DRUG

Romidepsin

Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.

DRUG

Lenalidomide

Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

11570

Memorial Sloan Kettering Cancer Center at Mercy, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center at Commack, Commack

06105

Saint Francis/Mount Sinai Regional Cancer Center, Hartford

68198-7680

University of Nebraska Medical Center, Omaha

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

Unknown

Weill Cornell Medical Center, New York

Sponsors
All Listed Sponsors
collaborator

St. Francis Hospital & Medical Center, Hartford CT

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of Nebraska

OTHER

collaborator

Celgene Corporation

INDUSTRY

collaborator

Biologics, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER